Brain pyrimidine nucleotide synthesis and Alzheimer disease

dc.contributor.authorPesini, Alba
dc.contributor.authorIglesias, Eldris
dc.contributor.authorBayona Bafaluy, M. Pilar
dc.contributor.authorGarrido Pérez, Nuria
dc.contributor.authorMeade, Patricia
dc.contributor.authorGaudó, Paula
dc.contributor.authorJimenez Salvador, Irene
dc.contributor.authorAndrés Benito, Pol
dc.contributor.authorMontoya, Julio
dc.contributor.authorFerrer, Isidro (Ferrer Abizanda)
dc.contributor.authorPesini, Pedro
dc.contributor.authorRuiz Pesini, Eduardo
dc.date.accessioned2020-10-13T14:41:23Z
dc.date.available2020-10-13T14:41:23Z
dc.date.issued2019-10-15
dc.date.updated2020-10-13T10:20:27Z
dc.description.abstractMany patients suffering late-onset Alzheimer disease show a deficit in respiratory complex IV activity. The de novo pyrimidine biosynthesis pathway connects with the mitochondrial respiratory chain upstream from respiratory complex IV. We hypothesized that these patients would have decreased pyrimidine nucleotide levels. Then, different cell processes for which these compounds are essential, such as neuronal membrane generation and maintenance and synapses production, would be compromised. Using a cell model, we show that inhibiting oxidative phosphorylation function reduces neuronal differentiation. Linking these processes to pyrimidine nucleotides, uridine treatment recovers neuronal differentiation. To unmask the importance of these pathways in Alzheimer disease, we firstly confirm the existence of the de novo pyrimidine biosynthesis pathway in adult human brain. Then, we report altered mRNA levels for genes from both de novo pyrimidine biosynthesis and pyrimidine salvage pathways in brain from patients with Alzheimer disease. Thus, uridine supplementation might be used as a therapy for those Alzheimer disease patients with low respiratory complex IV activity.
dc.format.extent30 p.
dc.format.mimetypeapplication/pdf
dc.identifier.pmid31560653
dc.identifier.urihttps://hdl.handle.net/2445/171192
dc.language.isoeng
dc.publisherImpact Journals Llc
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.18632/aging.102328
dc.relation.ispartofAging, 2019, vol. 11, num. 19, p. 8433-8462
dc.relation.urihttps://doi.org/10.18632/aging.102328
dc.rightscc by (c) Pesini et al., 2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationMalaltia d'Alzheimer
dc.subject.classificationPirimidines
dc.subject.otherAlzheimer's disease
dc.subject.otherPyrimidines
dc.titleBrain pyrimidine nucleotide synthesis and Alzheimer disease
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
PesiniA.pdf
Mida:
3.11 MB
Format:
Adobe Portable Document Format